88 related articles for article (PubMed ID: 19564097)
21. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
22. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.
Kubo K; Fleischhacker WW; Suzuki T; Yasui-Furukori N; Mimura M; Uchida H
Acta Psychiatr Scand; 2019 Feb; 139(2):108-116. PubMed ID: 30198163
[TBL] [Abstract][Full Text] [Related]
23. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
25. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.
Levine SZ; Leucht S
Schizophr Res; 2013 Apr; 145(1-3):125-7. PubMed ID: 23394742
[TBL] [Abstract][Full Text] [Related]
26. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
[TBL] [Abstract][Full Text] [Related]
27. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
Docherty JP; Baker RA; Eudicone J; Mathew S; Marcus RN; McQuade RD; Mankoski R
Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037
[TBL] [Abstract][Full Text] [Related]
28. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine.
Lin CH; Chou LS; Lin CH; Hsu CY; Chen YS; Lane HY
J Clin Psychiatry; 2007 Oct; 68(10):1522-7. PubMed ID: 17960966
[TBL] [Abstract][Full Text] [Related]
29. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
30. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial.
Joffe G; Terevnikov V; Joffe M; Stenberg JH; Burkin M; Tiihonen J
Schizophr Res; 2009 Mar; 108(1-3):245-51. PubMed ID: 19144501
[TBL] [Abstract][Full Text] [Related]
31. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
[TBL] [Abstract][Full Text] [Related]
32. Equipercentile linking of the BPRS and the PANSS.
Leucht S; Rothe P; Davis JM; Engel RR
Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
[TBL] [Abstract][Full Text] [Related]
33. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
34. Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS).
Khan A; Yavorsky WC; Liechti S; DiClemente G; Rothman B; Opler M; DeFries A; Jovic S
J Clin Psychopharmacol; 2013 Feb; 33(1):109-17. PubMed ID: 23277234
[TBL] [Abstract][Full Text] [Related]
35. Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia.
Lin CH; Chou LS; Lin CH; Hsu CY; Chen CC; Lane HY
J Clin Psychopharmacol; 2012 Dec; 32(6):773-7. PubMed ID: 23131876
[TBL] [Abstract][Full Text] [Related]
36. Early prediction of antipsychotic response in schizophrenia.
Correll CU; Malhotra AK; Kaushik S; McMeniman M; Kane JM
Am J Psychiatry; 2003 Nov; 160(11):2063-5. PubMed ID: 14594760
[TBL] [Abstract][Full Text] [Related]
37. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study.
Leucht S; Shamsi SA; Busch R; Kissling W; Kane JM
Schizophr Res; 2008 Apr; 101(1-3):312-9. PubMed ID: 18308513
[TBL] [Abstract][Full Text] [Related]
38. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
39. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
[TBL] [Abstract][Full Text] [Related]
40. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
